Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis.
Suwattee
Pitiporn
P
Chow
Steven
S
Berg
Brian C
BC
Warshaw
Erin M
EM
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002276:Carcinoid Tumor / Q000175:diagnosis / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology* / Q000503:physiopathology; D004890:Erythema / Q000139:chemically induced* / Q000188:drug therapy; D005500:Follow-Up Studies; D005533:Foot Dermatoses / Q000139:chemically induced*; D006229:Hand Dermatoses / Q000139:chemically induced*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa / Q000187:drug effects / Q000473:pathology; D052016:Mucositis / Q000139:chemically induced* / Q000188:drug therapy; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced* / Q000188:drug therapy; D000077210:Sunitinib; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib